Gary Robert Morrow, Ph.D., M.S.

Associate Director for Community Research
Coordinator of Research Training
University of Rochester Cancer Center
Ph.D., University of Rhode Island, 1975
No image available

Contact Information

University of Rochester School of Medicine and Dentistry
601 Elmwood Avenue, Box 704
Rochester, NY 14642


Phone: (585) 275-5513
Fax: (585) 461-5601
E-mail: gary_morrow@urmc.rochester.edu



Clinical Specialty
Research Overview
Selected Honors
Education
Academic Appointments
Hospital Appointments
Major Committees
Publications
Radiation Oncology Home

_________________

Clinical Specialty

Clinical Psychology

_________________

Research Overview

Current Awards
  • American Cancer Society, predicting side effects of cancer treatment

    2005, $1,716,026.

  • National Cancer Institute, assessing information needs of cancer patients undergoing chemotherapy and radiation therapy

    2002, $350,000.

  • Alza Pharmaceutical; A phase II placebo-controlled trial of once daily methylphenidate in cancer patients with symptoms of fatigue related to radiation therapy

    2000-2002, $210,000.

  • National Cancer Institute Grant throught NSABP, "NSABP Protocol P-2: A study of tamoxifen and raloxifene for the prevention of breast cancer," Principal Investigator for University of Rochester Cancer Center (URCC) Cancer Prevention Nework

    1999-2006, $620,000.

  • American Cancer Society, "Institutional Reasearch Grant Award," Principal Investigator

    1999-2002, $240,000.

  • United States Army Grant, "Preventing Fatigue in Women with Breast Cancer Treated with Chemotherapy," Principal Investigator

    1996-2001, $805,803.

  • Nathan Cummings Foundation Grant, "Group Therapy for Women with Newly Diagnosed Breast Cancer and its Impact on Health," Principal Investigator

    1992-1999, $175,200

    Supplement: 1993-1999, $90,000.

  • National Cancer Institute Grant, "University of Rochester Cancer Center Research Base for Community Clinical Oncology Program (CCOP)," Principal Investigator, 2U10-CA37420, 1991-2001

    2001, $645,000

  • National Cancer Institute Grant, "Counseling Intervention for Chemotherapy Side Effects," Principal Investigator, R18-CA26832

    (most recent renewal)1994-1999, $1,297,644.



_________________

Selected Honors

  • American Cancer Society Scientific Advisory Committee on Institutional Research Grants, 1991;
  • Vice Chairman, 1993; Chairman, 1994
  • Evan and Marion Helfaer Distinguished Lectureship, Medical College of Wisconsin, 1989
  • New York State Governors Commission on Cancer Control, 1989-present
  • Irene Lefton Leukemia Foundation Lectureship, November, 1988
  • Board of Scientific Counselors, Illinois Cancer Council, 1987
  • Research Career Development Award, 1985-90
  • American Cancer Society Council on Research and Investigative Awards, 1984-1989
  • Who's Who in the Biobehavioral Science, 1983
  • Who's Who in Frontier Science and Technology, 1983
  • Fellow, American Psychological Association, Division 38 (Health Psychology), 1983
  • Academy of Behavioral Medicine Research, 1982
  • American Cancer Society Scientific Advisory Committee on Clinical Investigations: Psychosocial and Behavioral Research, 1980-1984; Chairman, 1983-84
  • American Cancer Society Scientific Advisory Committee on Prevention, Diagnosis and Therapy, 1978-80
  • NDEA Fellowship, 1974-75
  • Dean's Award (outstanding technical article of the year), Notre Dame, 1967
  • Pi Tau Sigma (National Mechanical Engineering Honorary), Notre Dame, Chapter President, 1966-67
  • Tau Kappa Alpha (National Forensic Honorary), Notre Dame, Chapter President, 1966-67
  • Sophomore Engineer of the Year, Notre Dame, 1965
  • Naval ROTC Scholarship, 1963-67
  • Distinguished Paper Award, MAPSS, Temple University, 1961


_________________

Publications

  1. Morrow, G.R., Hickok, J.T., Roscoe, J.A., Raubertas, R.F., Andrews, P.L.R. et al. The differential effects of Paroxetine on fatigue and depression: A URCC CCOP randomized, double-blind clinical trial of 479 patients receiving chemotherapy from community oncologists. J Clinical Oncology. (In press)
  2. Shields, C.G., Morrow, G.R., Griggs, J.J., Mallinger, J., Roscoe, J.A., Wade, J.L., Dakhil, S.R., Fitch, T.R. Decision role preferences of patients receiving adjuvant cancer treatment: A university of Rochester Cancer Center Community Clinical Oncology Program (URCC CCOP). Supportive Cancer Therapy. Supportive Cancer Therapy. 2004, 83:87-89.
  3. Pandya, K.J., Thummala, A.R., Griggs, J.J., Rosenblatt, J.D., Sahasrabudhe, D.M., Guttuso, T.J., Morrow, G.R., Roscoe, J.A. Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast Cancer Research and Treatment. 2004, 83(1):87-89.
  4. Hickok, J.T., Roscoe, J.A., Morrow, G.R., King, D.K., Atkins, J.N., Fitch, T.R. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5HT3 antiemetics: A URCC CCOP Study of 360 cancer patients treated in the community. Cancer. 2003, 97:2880-86
  5. Roscoe, J.A., Morrow, G.R., Hickok, J.T., Bushunow, P. et al. The efficacy of acupressure and acustimultion wrist bands for the relief of chemotherapy-induced nausea and vomiting: A URCC CCOP multicenter study. Journal of Pain and Symptom Management. 2003, 26:731-42.
  6. Kim, Y., Morrow, G.R., Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Supportive Care in Cancer. 2003, 11(3):171-77.
  7. Morrow, G.R., Hickok, J.T., Andrews, P.L.R., and Stern, R. Reduction in serum cortisol following platinum- based chemotherapy. Psychophysiology. 2002, 39:491-95.
  8. Kim,Y., Roscoe, J.A., Morrow, G.R. The effects of information and negative affect on severity of side effects from radiation therapy for prostate cancer. Supportive Care in Cancer. 2002, 10:416-21.
  9. Matteson, S., Roscoe, J.A., Hickok J.T., Morrow, G.R. The role of behavioral conditioning in the development of nausea. Am J Obstet Gynecol. 2002, 186:S239-S243.
  10. Morrow, G.R., Andrews, P.L.R., Hickok, J.T., Roscoe, J.A., Matteson, S. Fatigue associated with cancer and its treatment. Supportive Care in Cancer. 2002, 10:389-98.
  11. Roscoe, J.A., Morrow, G.R., Bushunow, P., Tian, L., Matteson, S. Acustimulation wristbands for the relief of chemotherapy-induced nausea. Alternative Therapies in Health & Medicine. 2002, 8:56-63.
  12. Roscoe, J.A., Morrow, G.R., Hickok, J.T., Bushunow, P., Matteson, S., Rakita, D., Andrews, P.L.R. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Supportive Care in Cancer. 2002, 10:329-36.
  13. Morrow, G.R., Roscoe J.A., Hickok, J.T., Andrews, P.L.R., Matteson, S. Nausea and emesis: Evidence for a biobehavioral perspective. Supportive Care in Cancer. 2002, 10:96-105.
  14. Koopman, C., Butler, L.D., Classen, C., GieseDavis, J., Morrow, G.R., Westendorf, J., Banerjee, T., Spiegel, D.
  15. Traumatic stress symptoms among women with recently diagnosed primary breast cancer. Journal of Traumatic Stress. 2002, 15(4):277-87.
  16. Gianaros, P.J., Stern, R.M., Morrow, G.R., Hickok, J.T. Relationship of gastric myoelectrical and cardiac parasympathetic activity to chemotherapy-induced nausea. Journal of Psychosomatic Research. 2001, 50:263-66.
  17. Hickok, J.T., Roscoe, J.A., Morrow, G.R. The role of patients' expectations in the development of anticipatory nausea related to chemotherapy for cancer. Journal of Pain & Symptom Management. 2001, 22:843-50.
  18. Pandya, K.J., Raubertas, R.F., Flynn, P.J., Morrow, G.R. et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000, 132:788-93.
  19. Roscoe, J.A., Morrow, G.R., Hickok, J.T., Stern, R.M. Nausea and vomiting remain a significant clinical problem: Trends over time in controlling chemotherapy-induced nausea and vomiting in 1,413 patients treated in community clinical practices. Journal of Pain and Symptom Management. 2000, 20:113-121.
  20. Morrow, G.R., Andrews, P.L.R., Hickok, J.T., Stern, R.M. Vagal changes following cancer chemotherapy; implications for the development of nausea. Psychophysiology. 2000, 37:378-84.
  21. Roscoe, J.A., Hickok, J.T., Morrow, G.R. Patient expectations as predictor of chemotherapy-induced nausea. Annals of Behavioral Medicine. 2000, 22:121-126.
  22. Nair, M.G., Hickok, J.T., Roscoe, J.A., Morrow, G.R. Sources of information used by patients to learn about chemotherapy side effects. J of Cancer Education. 2000, 15:19-22.
  23. Hickok, J.T., Roscoe, J.A., Morrow, G.R., Stern, R.M., Yang, B., Flynn, P.J., Hynes, H.E., Kirshner, J.J., Rosenbluth, R.J. Use of 5-HT3 receptor antagonists to prevent nausea and vomiting caused by chemotherapy for breast cancer in community practice settings. Cancer. 1999, 86:64-71.
  24. Spiegel, D., Morrow, G.R., Classen, C., Raubertas, R., Stott, P.B., Mudaliar, N. et al. Group psychotherapy for recently diagnosed breast cancer patients: A multicenter feasibility study. Psychooncology. 1999, 8: 482-93.
  25. Morrow, G.R., Hickok, J.T., DuBeshter, B., Lipshultz, S. Changes in clinical measures of autonomic nervous system function related to cancer chemotherapy induced nausea. Journal of the Autonomic Nervous System. 1999, 78:57-63.
  26. Gralla R.J., Osoba, D., Kris, M.G., Kirkbrid, P., Hesketh, P.J., Chinnery, L.W., Morrow, G.R. et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999, 17:2971-94.
  27. Morrow, G.R., Roscoe, J.A., Hickok, J.T., Stern, R.M., Pierce, H.I., King, D.B., Banerjee, T.K., Weiden, P.
  28. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Hunting). 1998, 12:32-37.
  29. Morrow, G.R., Roscoe, J.A., Kirshner, J.J., Hynes, H.E., Rosenbluth, R.J. Anticipatory nausea and vomiting:
  30. In the era of 5-HT3 antiemetics. Supportive Care in Cancer. 1998, 6:244-247.
  31. Morrow, G.R., Roscoe, J.A., Hynes, H.E., Flynn, P.J., Pierce, H.I., Burish, T. Progress in reducing anticipatory nausea and vomiting: A study of community practice. Supportive Care in Cancer. 1998, 6:46-50.
  32. Morrow, G.R., Ballatori, E., Groshen, S., Olver, I. Statistical considerations in the design, conduct and analyses of antiemetic clinical trials. An emerging consensus. Supportive Care in Cancer. 1998, 6(3):261-265.
  33. Classen, C., Abramson, S., Angell, K., Atkinson, A., Desch, C., Vinciguerra, V.P., Rosenbluth, R.J., Kirshner, J.J., Hart, R., Morrow, G.R., Spiegel, D. Effectiveness of a training program for enhancing therapists' understanding of the supportive-expressive treatment model for breast cancer groups. Journal of Psychotherapy Practice and Research. 1997, 6(3):211-218.
  34. Muth, E.R., Morrow, G.R., Jiang, W., Stern, R.M., Dubeshter, B. Cardiac spectral power reflects parasympathetic but not sympathetic nervous system activity in a clinical population. Journal of the Autonomic Nervous System. 1996, 61(2):201-203.

_________________

Back to the Radiation Oncology Home Page

Last Modified: Dec. 2005